Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Rufloxacin . hydrochloride

Fluoroquinolone antibacterial agent
 
ALX-380-300-M250 250 mg 222.00 USD
Do you need bulk/larger quantities?
 
Fluoroquinolone antibacterial agent. Structurally similar to ofloxacin (Prod. No. ALX-380-297). Specific inhibitor of bacterial DNA gyrase (topoisomerase). Inhibits B-cell differentiation. Shows photosensitizing effects.

Product Specification

Alternative Name:6-Fluoro-2,3-dihydro-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzothiazine-6-carboxylic acid . hydrochloride, MF-934 . hydrochloride
 
Formula:C17H18FN3O3S . HCl
 
MW:363.4 . 36.5
 
CAS:106017-08-7
 
MI:14: 8294
 
Purity:≥98% (Assay)
 
Identity:Identity determined by IR.
 
Appearance:Off-white to light green crystalline solid.
 
Solubility:Sparingly soluble in water; very slightly soluble in methanol; almost insoluble in chloroform or acetic acid.
 
Shipping:Ambient
 
Long Term Storage:-20°C
 
380-300
Please mouse over
380-300

Product Literature References

Rufloxacin-induced photosensitization in yeast: A. Catalfo, et al.; Photochem. Photobiol. Sci. 6, 181 (2007), Abstract;
Penetration of rufloxacin into the cerebrospinal fluid in patients with inflamed and uninflamed meninges: M.V. Moretti, et al.; Antimicrob. Agents Chemother. 44, 73 (2000), Abstract; Full Text
Molecular mechanisms of photosensitization induced by drugs. XII. Photochemistry and photosensitization of rufloxacin: an unusual photodegradation path for the antibacterials containing a fluoroquinolone-like chromophore: G. Condorelli, et al.; Photochem. Photobiol. 70, 280 (1999), Abstract;
Comparison of the mechanism of action and resistance of two new fluoroquinolones, rufloxacin and MF961 with those of ofloxacin and fleroxacin in gram-negative and gram-positive bacteria: L.J. Piddock, et al.; J. Antimicrob. Chemother. 31, 855 (1993), Abstract;
Double-blind, comparative study of rufloxacin once daily versus amoxicillin three times a day in treatment of outpatients with exacerbations of chronic bronchitis: W. Klietmann, et al.; Antimicrob. Agents Chemother. 37, 2298 (1993), Abstract; Full Text
Rufloxacin once daily versus ofloxacin twice daily for treatment of complicated cystitis and upper urinary tract infections. Italian Multicentre UTI Rufloxacin Group: R. Mattina, et al.; Infection 21, 106 (1993), Abstract;
Effect of rufloxacin on in-vitro proliferation and differentiation of human mononuclear cells: S. Gollapudi, et al.; J. Antimicrob. Chemother. 29, 669 (1992), Abstract;
Multiple-dose pharmacokinetics and safety of rufloxacin in normal volunteers: J.C. Kisicki, et al.; Antimicrob. Agents Chemother. 36, 1296 (1992), Abstract; Full Text
The in-vitro activity of two new quinolones: rufloxacin and MF 961: R. Wise, et al.; J. Antimicrob. Chemother. 29, 649 (1992), Abstract;
Quinolonecarboxylic acids. 2. Synthesis and antibacterial evaluation of 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acids: V. Cecchetti, et al.; J. Med. Chem. 30, 465 (1987), Abstract;

Related Products

Ofloxacin 

Fluoroquinolone antibacterial agent
82419-36-1, ≥98% (UHPLC) | Print as PDF
 
ALX-380-297-G005 5 g 58.00 USD
Do you need bulk/larger quantities?
 

Product Toolbox

PRODUCT RESOURCES

Datasheet
MSDS
Certificate of Analysis

RELATED PRODUCTS

By target:
DNA gyrase
By biological activity:
DNA gyrase Inhibitor
By catalog section:

PRODUCT SUPPORT

FAQs
Technical Service
Customer Service

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,